MammaPrint and BluePrint Breast Cancer Testing
What the tests measure and how results support treatment discussions
Written byTeam Oncquest
DJ
Reviewer
Reviewer profile
Dr. Jasmine Kaur
Dr. Jasmine Kaur is a Consultant in R&D in the Molecular Biology and Genomics Department at Oncquest Laboratories.
10
Articles reviewedof 11 in the library
4
Topics coveredAcross published contributions
Oct 202026
Latest article updatePublished content
About
Background
Dr. Jasmine Kaur is a Consultant in R&D in the Molecular Biology and Genomics Department at Oncquest Laboratories. She holds a PhD in Biotechnology from Jamia Hamdard, New Delhi, and an MPhil, with more than seven years of post-PhD experience in molecular diagnostics. Her work includes developing, standardising and validating clinically relevant molecular assays and analysing genomic biomarkers for medical testing.
Topics covered
Review record
Reviewed Articles 10
3 articles in the selected topic.
Molecular Subtypes of Breast Cancer
Luminal A, Luminal B, HER2 and Basal types—and how they differ from routine pathology labels
8 min read
Written byTeam Oncquest
Understanding MammaPrint Results
Risk categories, the MammaPrint Index and what to discuss when the report arrives
9 min read
Written byTeam Oncquest